Fluzoparib+Apatinib

Phase 2Small molecule

XXiaohua Wu MD

Fluzoparib+Apatinib is one of 70 small molecule programs targeting Ovarian Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CarcinomaActive, not recruiting

Ovarian CancerActive, not recruiting

Ovarian CarcinomaPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Votrient

Novartis

Phase 3

8 3

Perjeta

Roche

Phase 3

3 4

Aromasin

Pfizer

Phase 3

2 5

Piqray

Novartis

Phase 3

1 6

Trastuzumab Deruxtecan

AstraZeneca

Phase 3

1 7

Carboplatin/paclitaxel

AstraZeneca

Phase 3

1 8

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

2 9

Azenosertib

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

2 10

JSKN003

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Ovarian Carcinoma

NCT05479487

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Unknown status·GGuangxi Medical University·Phase 2·NCT06161272·80 enrolled

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04517357·100 enrolled

Ovarian Carcinoma1 trial

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Not yet recruiting·XXiaohua Wu MD·Phase 2·NCT05479487·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Fluzoparib+Apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluzoparib+Apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluzoparib+Apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiaohua Wu MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXiaohua Wu MD

Fluzoparib+Apatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Ovarian Cancer2 trials

Ovarian Carcinoma1 trial

References

Drug Info

Quick Facts

Related News